Shenzhen Bay Laboratory

HealthCare Policy Scholar Contact Us Business email

中文





Homepage

/

Scholar

Uptake of Artificial Intelligence (AI) and Machine Learning

2020-03-20

Over the past year, pharma and biotech companies have made pacts with tech giants to reap the rewards of AI and machine learning. Earlier this year, Pfizer announced it will collaborate with an AI sta

MORE

Over the past year, pharma and biotech companies have made pacts with tech giants to reap the rewards of AI and machine learning. Earlier this year, Pfizer announced it will collaborate with an AI sta

Emphasis on Targeted Therapies

2020-03-20

Personalized medicine refers to therapies that are designed based on the genetic and molecular makeup of a patient. In principle, an individualized treatment should be more effective at treating a pat

MORE

Personalized medicine refers to therapies that are designed based on the genetic and molecular makeup of a patient. In principle, an individualized treatment should be more effective at treating a pat

Widespread Wearable Technology

2020-03-20

For 2020, manufacturers and consumers will have to be wary of potential cybersecurity risks. They can expect tighter regulations on such devices especially if they deal with patient health information

MORE

For 2020, manufacturers and consumers will have to be wary of potential cybersecurity risks. They can expect tighter regulations on such devices especially if they deal with patient health information

Next-Generation Genetics & Gene Editing

2020-03-20

Scientists have also made great strides in the field of gene editing. Among the most notable accomplishments of the year are the launch of America’s first clinical trial involving CRISPR-treated cells

MORE

Scientists have also made great strides in the field of gene editing. Among the most notable accomplishments of the year are the launch of America’s first clinical trial involving CRISPR-treated cells

Rise in Biosimilars & Generics

2020-03-20

A biosimilar is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product, according to the FDA. In other words, biosimilars do not necessarily con

MORE

A biosimilar is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product, according to the FDA. In other words, biosimilars do not necessarily con

2

About UsBrief Introduction Opening Remarks for 2020 Organization and Structure
Research & DevelopmentFields Groups Skills&Platforms
CareersValues Activities Recruiting
LaboratoryChemical Synthesis Peptide Drug Development Center Herb & Natural Plant Extract Preparation & Formulation Quality Analysis Center
News and EventsAcademic Spotlights Industry and Business Conferences Agenda

log

Data Protection / Policy / OA /